0RA9 Stock Chart & Stats
€108.40
€0.00(0.00%)
At close: 4:00 PM EDT
€108.40
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€60.70 - €139.00
Previous CloseN/A
Volume1.88K
Average Volume (3M)1.81K
Market Cap
€7.55B
Enterprise Value€8.80K
Total Cash (Recent Filing)€410.68M
Total Debt (Recent Filing)€1.21M
Price to Earnings (P/E)―
Beta3.52
Next Earnings
Dec 14, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.71
Shares Outstanding87,350,044
10 Day Avg. Volume1,856
30 Day Avg. Volume1,808
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€132.00Price Target Upside21.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.29
Revenue Forecast (FY)€3.80M
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet FlexibilityThe improved 2025 balance sheet provides greater financial flexibility while Abivax funds clinical development. Low leverage can reduce near-term financing pressure and leave more room to allocate capital toward advancing obefazimod and preparing for potential commercialization.
Focused Lead Drug PlatformA single oral lead program with potential applications beyond ulcerative colitis gives Abivax a focused development strategy and possible expansion path. If clinical and regulatory progress continues, the platform could support multiple indications from one immunomodulatory mechanism.
Commercialization Infrastructure StrengthenedThe appointments add leadership experience in inflammatory bowel disease, commercialization, launch, commercial CMC, quality, and IT. That strengthens organizational readiness as Abivax advances its lead program toward a potential transition from clinical development to commercial operations.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means Abivax cannot currently fund research and operations from internally generated cash. Continued high burn increases the importance of future financing and can constrain development choices if capital access becomes less favorable.
Deepening Losses And Absent Commercial RevenueWidening losses combined with zero reported revenue show that the business remains dependent on successful clinical development rather than an established commercial earnings base. This leaves profitability uncertain and makes future returns highly dependent on regulatory and launch execution.
Dependence On External FinancingReliance on public-market funding or potential collaboration payments creates an ongoing financing requirement while the lead candidate remains uncommercialized. Additional capital needs may dilute existing holders or restrict strategic flexibility if fundraising terms are unfavorable.
Abivax SA News
0RA9 FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest share price was €60.70 and its highest was €139.00 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €7.55B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is Dec 14, 2026 which is in 80 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on Sep 21, 2026. The company reported -€1.47 earnings per share for the quarter, missing the consensus estimate of -€0.801 by -€0.669.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Undervalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.87.
How many shares outstanding does Abivax SA have?
Abivax SA has 87,350,044 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€1.47 in its last earnings report, missing expectations of -€0.801. Following the earnings report the stock price went down -4.633%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in GB:0RA9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
0RA9 Stock 12 Month Forecast
Average Price Target
€132.00
▲(21.77% Upside)